Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Opana, Numorphan, Oxymorphone ER
Oxymorphone is a potent opioid analgesic indicated for the management of moderate to severe acute and chronic pain when a continuous, around-the-clock analgesic is needed for an extended period of time. It is a semi-synthetic opioid agonist that acts primarily on mu-opioid receptors in the central nervous system, mimicking the effects of endogenous endorphins to produce analgesia. Oxymorphone is classified as a Schedule II controlled substance due to its high potential for abuse and dependence.
For the management of moderate to severe acute and chronic pain requiring continuous, around-the-clock opioid analgesia.
Oxymorphone hydrochloride extended-release tablets are associated with serious risks, including abuse and misuse, addiction, overdose, and death. Assess each patient's risk prior to prescribing oxymorphone hydrochloride extended-release tablets, and monitor all patients regularly for the development of these behaviors or conditions.
Outcome:
Increased sedation, respiratory depression
Mechanism:
Additive CNS depressant effects
Outcome:
Increased constipation, urinary retention
Mechanism:
Additive anticholinergic effects
Outcome:
Potential for increased oxymorphone levels
Mechanism:
Inhibition of CYP3A4 enzyme
Most likely new formulation: abuse-deterrent extended-release formulation (2024, 70% confidence)
Based on current usage trends and safety profile, there is a low (5%) likelihood of increased regulatory restrictions on oxymorphone in the next 2 years.
Opioid Analgesic, Narcotic
Morphinan Derivative